

1 **Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an**  
2 **epidemic driven by 501Y.v2 (lineage B.1.351) in the Eastern Cape, South Africa**

3

4 **Oluwakemi Laguda Akingba<sup>a,b</sup>, Kaitlin Sprong<sup>a,b</sup> and Diana Ruth Hardie<sup>a,c</sup>**

5

6

7 <sup>a</sup>National Health Laboratory Service, South Africa

8 <sup>b</sup>Department of Laboratory Medicine and Pathology, Faculty of Health Sciences, Walter  
9 Sisulu University, Mthatha, South Africa

10 <sup>c</sup>Division of Medical Virology, Department of Pathology, University of Cape Town, Cape  
11 Town, South Africa

12 word count: 1256

13

14 Corresponding author: Diana Hardie, C18 Laboratory, Groote Schuur Hospital, Anzio Rd  
15 Observatory, 7925, Cape Town, South Africa

16 E mail: [diana.hardie@uct.ac.za](mailto:diana.hardie@uct.ac.za)

17 Oluwakemi Laguda Akingba

18 e mail: [Oluwakemi.LA@nhls.ac.za](mailto:Oluwakemi.LA@nhls.ac.za)

19 Kaitlin Sprong

20 e mail: [Kaitlin.sprong@nhls.ac.za](mailto:Kaitlin.sprong@nhls.ac.za)

21

22

23 **Abstract:**

24 Background: South Africa was the African country most severely affected by the SARS-CoV-  
25 2 pandemic during 2020, experiencing 2 waves of infection. During the first wave,  
26 diagnostics were largely based on reverse transcription-linked PCR (RT-PCR). The Abbott  
27 PanBio antigen test was deployed during the 2nd wave which was driven by emergence of  
28 the 501Y.v2 variant. At the time of evaluation in mid-November 2020, 501Y.v2 was the  
29 dominant circulating virus in Nelson Mandela Bay, in the Eastern Cape Province.

30 Methods: A prospective diagnostic evaluation study was undertaken, during a period of  
31 high community transmission, to evaluate the field performance of the PanBio antigen RTD.  
32 Testing was conducted at mobile community testing centres on 677 ambulant patients  
33 seeking SARS-CoV-2 testing. RT-PCR was performed on the original naso-pharyngeal antigen  
34 swabs to evaluate test performance.

35 Results: Of 146 RT-PCR positive individuals, 101 were RTD positive in the clinic. The antigen  
36 RTD had an overall sensitivity of 69.2% (95%CI 61.4, 75.8) and specificity of 99.0% (95%CI  
37 98.8, 99.3) in this clinical context. Sensitivity was strongly dependent on the amount of  
38 virus in clinical samples, as reflected by the PCR cycle threshold (CT) value, with 100%  
39 detection in samples where the CT was <20, 96% with CT between 20-25, 89% with CT  
40 between 26-30 and 64% when CT was 31-35.

41 Conclusions: The assay reliably detected 501Y.v2 infections in ambulatory ill patients. Assay  
42 sensitivity was >90% in patients with high viral loads who are expected to be most  
43 infectious. Negative and positive predictive values were also >90%.

44 **Keywords:**

45 SARS-CoV-2

46 501Y.v2

47 B.1.351

48 Rapid antigen test

49 Point of care

50 COVID-19

51 **Abbreviations:**

52 COVID-19. Coronavirus disease 2019; CT, cycle threshold; SARS-CoV-2, severe acute  
53 respiratory syndrome coronavirus 2; RTD, rapid test device; PCR, polymerase chain reaction;  
54 RT-PCR, reverse transcription polymerase chain reaction; WHO, world health organisation;  
55 501Y.v2, 501Y variant 2; IQR, interquartile range; NP, nasopharyngeal; GISAID, global  
56 initiative for sharing all influenza data;

57

58

59 **Background:**

60 During 2020 South Africa was the African country most severely affected by the SARS-CoV-2  
61 pandemic with more than 1 380 000 laboratory confirmed cases and 83 918 excess  
62 deaths[1]. During this period, the country experienced 2 waves of infection[2]. Provision of  
63 an effective diagnostic service proved to be challenging. RT-PCR is the gold standard assay  
64 for SARS-CoV-2 diagnosis, however, in the context of high disease prevalence, laboratory  
65 systems may easily become overwhelmed. Rapid diagnostics such as antigen tests that can  
66 be performed at point of care provide a welcome solution. Their main drawback is lower  
67 sensitivity[3]. The WHO advises that assays that meet minimum performance requirements  
68 (>80% sensitivity, >97% specificity in the first 7 days of symptoms) can be used in contexts  
69 where nucleic acid-based testing is unavailable, or where turn-around times are  
70 prolonged[4]. The Abbott PanBio rapid SARS-CoV-2 antigen assay has fulfilled these criteria  
71 in evaluations in several studies [5][6]

72 This assay was deployed during the 2<sup>nd</sup> wave in South Africa which first became apparent in  
73 the Eastern Cape Province in October/November 2020. Increased disease activity was  
74 associated with emergence of a new variant, namely 501Y.v2[7]. This variant, now referred  
75 to as lineage B.1.351, first detected in October 2020 rapidly became the predominant virus,  
76 across the country, due to its higher transmissibility[8]. At the time of evaluation in mid-  
77 November 2020, it was the dominant circulating virus, responsible for around 84% of  
78 infections in Nelson Mandela Bay, estimate based on genomes submitted to global initiative  
79 for sharing all influenza data (GISAID) over this time period [9]. This prospective diagnostic  
80 evaluation study was designed to evaluate the field performance of the PanBio assay, but  
81 also provides evidence on its performance in individuals infected with 501Y.v2. Another  
82 novel aspect to this study is that RT PCR was performed on the same swab used for antigen  
83 testing, which obviated the need to collect further samples from patients and provided a  
84 more direct comparison with the antigen result.

85 **Methods and results:**

86 Prospective diagnostic evaluation study in Nelson Mandela Bay municipality, Eastern Cape  
87 South Africa during a period of high disease prevalence, using nasopharyngeal swabs to  
88 determine the accuracy of Abbott PanBio COVID-19 antigen RTD.


89 **Verifying that used antigen swabs were suitable for PCR:**

90 44 paired swabs were collected from symptomatic patients, one nylon tip, standard issue  
91 swab for PCR and the flocked antigen swab from the PanBio test kit. SARSCoV-2 PCR was  
92 done on used antigen and matched nylon swabs.

93 The used antigen swab was prepared for PCR as follows: 1 mL saline was added to the swab  
94 container using a filter tip. The sample was vortexed and allowed to stand 2 minutes. The  
95 bottom cap was opened and fluid bled into a sterile vial. The matching PCR swab was  
96 snipped into a vial containing 1.5 ml normal saline and vortexed.

97 Paired samples were extracted on the EasyMag (bioMerieux) platform. RT-PCR was done  
98 using the Seegene nCoV assay with amplification on BioRad CFX realTime PCR machine. For  
99 PCR positive swabs, mean CT values of the 3 assay targets were compared.

100 Of the 44 paired samples, 13 were antigen positive. 26 were concordantly PCR negative,  
101 one sample was PCR positive on the antigen swab, but negative on the regular swab and 17  
102 samples were concordantly PCR positive. When comparing mean CT values of the paired  
103 swabs, the antigen swab had values of 2 CTs lower than the swab collected for PCR.  
104 Wilcoxon signed-rank test p0.0073. (figure 1)



105

106

107 **Figure 1: Average CT values of PCR positive paired antigen vs regular swabs are compared: The**  
108 **range of CT values from PCR of the antigen swab were on average 2 CTs lower than for those from**  
109 **the standard swabs. Wilcoxon signed-rank test p0.0073.**

#### 110 **Study protocol:**

111 Between 17 and 20 November 2020 mobile clinics ran community testing campaigns at 6  
112 sites in Nelson Mandela Bay. Symptomatic patients were invited to undergo antigen testing.  
113 Nasopharyngeal (NP) swabs were tested using the PanBio SARS-CoV-2 RTD. Results were  
114 communicated to patients immediately. The used swabs were sent for PCR. RT-PCR:  
115 Seegene nCoV assay (BioRad CFX platform) was performed on the same swab used for  
116 antigen testing. (as described)

117 A total of 677 patients from 6 mobile clinics were tested by both antigen and PCR. Patients  
118 were ambulant and seeking COVID testing. They ranged in age range from 3-85 years; 59%  
119 were female.


120 Of these, 101 (14.9%) were antigen positive in the clinic. With PCR, 146 samples (21.4%)  
121 were reported as positive, 19 (2.8%) as inconclusive (single target positive, CT>38) and 509  
122 (75.2%) were negative for both tests. Inconclusive samples were excluded from analysis as  
123 their significance was unresolved.

124 **Antigen test performance:**


125 Using PCR as the reference standard, the antigen test had an overall sensitivity (positive  
126 percent agreement) of 69.17% (95%CI 61.44, 75.80) and specificity (negative percent  
127 agreement) of 99.02% (95%CI 98.78, 99.26) in this clinical context.

128 Sensitivity was strongly dependent on the quantity of virus in clinical samples, as reflected  
129 by the CT value, with 100% detection by the antigen test in samples where the CT was <20,  
130 95.5% with CT between 20-25, 89.3% with CT between 26-30 and 64,3% when CT was 31-35.  
131 The CT values of antigen positive and negative samples are shown (Figures 2 a, b)

132 The antigen assay was positive in 3 PCR negative patients. Given the prevalence of infection  
133 of 21% (as determined by PCR) the predictive value of a negative test was 91.9% and that of  
134 a positive test was 97.12%.



135



136


137 **Figure 2 (a) Compares the number of antigen positive and negative samples according to CT**  
138 **category values obtained in PCR, (b) Compares the percentage of antigen positive samples**  
139 **according to virus levels, as reflected by the mean CT value.**

140

#### 141 **Characteristics of PCR positive samples:**

142 In the 146 PCR positive patients, CT values ranged from 17.4 to 41.3, median 30.1. As  
143 expected, the median CT and interquartile range (IQR) was lower in antigen positive samples  
144 at 28.7 (IQR 25.3-31.3). In comparison, the median and IQR of CT of antigen negatives was  
145 35.8 (IQR 32.7-37.1). (figure 3)

146



147

148 **Figure 3: Compares the range of CT values obtained on antigen positive and negative samples by**  
149 **reference PCR. Median and IQR values are given.**

150

### 151 **Discussion:**

152 This study took place during a period of high community transmission associated with  
153 emergence of the 501Y.v2 variant in the Eastern Cape. PCR was performed directly on the  
154 antigen swab after testing which enabled a direct comparison to be made between antigen  
155 reactivity and PCR on the same sample. Overall, the PanBio antigen test had a sensitivity of  
156 69.17% and specificity of 99.0%. The sensitivity is below the 80% WHO benchmark[4].  
157 However, context is key. Testing was performed on unselected symptomatic individuals  
158 who requested testing, irrespective of symptom duration. This probably accounts for the  
159 fact that 50% of PCR positive patients had CT values > 30, indicating that on average  
160 sampling may have occurred later during infection than recommended for maximum  
161 performance. Nonetheless performance was good in patients with CTs <30. In this range,  
162 sensitivity was 91.3%. This concordance (using distinctly different technologies) suggests  
163 that the 501Y.v2 was reliably detected by the RTD and at an expected level of frequency  
164 when compared with PCR.

165 Assay specificity was similarly good at 99% and the predictive value of a positive test was  
166 95%. This fulfils the WHO benchmark specificity requirements for deployment of this  
167 assay[4].

168 2 factors could compromise detection of the 501Y.v2 variant; namely amino acid changes in  
169 the region of the nucleocapsid protein targeted by kit antibodies, or reduced virus shedding  
170 in respiratory tract samples. The higher infectivity of the variant makes the latter  
171 explanation unlikely and preliminary evidence does not support it. 501Y.v2 has a single  
172 amino acid change in the linker region of the nucleocapsid protein, namely N205I [9]. As  
173 this amino acid is located in an unstructured region[10], it should not affect binding of kit  
174 antibodies.

175 The main limitation was that it was not feasible to confirm 501Y.v2 infection in positive  
176 cases. This was inferred from the fact that resurgence in this district was overwhelmingly  
177 due to 501Y.v2, based on contemporaneous genomes submitted to GISAID [9].

178

#### 179 **Conclusion:**

180 The assay reliably detected 501Y.v2 virus infection in ambulatory ill patients in this high  
181 prevalence community setting. Sensitivity was >90% in patients with high viral loads who  
182 are expected to be most infectious. To optimise the use of antigen RDTs in different and  
183 changing circumstances, clinical predictors and the epidemiological context should be  
184 considered when deciding how to deploy these assays.

#### 185 **Ethics:**

186 Ethical approval was obtained from the University of Cape Town Human Research Ethics Committee  
187 (UCT HREC 862.2020).

#### 188 **Informed consent:**

189 Patients were willing participants and gave verbal consent to diagnostic testing. Data was  
190 anonymised and delinked.

#### 191 **Author contributions:**

192 Study concept and design: DH, OL

193 Conduct of study, sample testing: OL, KS

194 Manuscript write up: DH, OL, KS

195 All authors approved the final manuscript

196 **Declaration of competing interest:**

197 The authors report no competing interests.

198 **Funding:**

199 No funding was given for this study.

200 **References:**

201 [1] SAMRC, Report on Weekly Deaths in South Africa, South Africa  
202 Med. Res. Counc. 2021 (2020) 1.

203 <https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa>.

204 [2] L.B. Waasila Jassat<sup>1</sup>, Cheryl Cohen<sup>2</sup>, Caroline Mudara<sup>1</sup>, THE  
205 FIRST AND SECOND WAVE OF COVID-19 IN THREE DISTRICTS OF  
206 SOUTH AFRICA, COVID-19 Spec. PUBLIC Heal. Surveill. Bull.  
207 COVID-19 Spec. PUBLIC Heal. Surveill. Bull. 18 (2021) 1–24.

208 [3] J. Cunningham, S. Beese, J. Dretzke, H. Im, P. Mj, H. Im, P. Mj, L.  
209 Hoo, L. Mmg, R. Spijker, V.D.B. A, diagnosis of SARS-CoV-2  
210 infection ( Review ), (2020).

211 <https://doi.org/10.1002/14651858.CD013705>.[www.cochranelibr](http://www.cochranelibrary.com)  
212 [ary.com](http://www.cochranelibrary.com).

213 [4] WHO, Antigen-detection in the diagnosis of SARS-CoV-2 infection  
214 using rapid immunoassays Interim guidance, 11 September  
215 2020., World Heal. Organ. (2020).

- 216 <https://apps.who.int/iris/handle/10665/334253>.
- 217 [5] M. Linares, R. Pérez-Tanoira, A. Carrero, J. Romanyk, F. Pérez-  
218 García, P. Gómez-Herruz, T. Arroyo, J. Cuadros, Panbio antigen  
219 rapid test is reliable to diagnose SARS-CoV-2 infection in the first  
220 7 days after the onset of symptoms, *J. Clin. Virol.* 133 (2020) 3–6.  
221 <https://doi.org/10.1016/j.jcv.2020.104659>.
- 222 [6] B. Mühlemann, M. Zuchowski, W. Karen, J. Lei, Comparison of  
223 seven commercial SARS-CoV-2 rapid point of care antigen assays,  
224 *MedRxiv.* (2020).  
225 <https://doi.org/https://doi.org/10.1101/2020.11.12.20230292>.
- 226 [7] H. Tegally, E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca,  
227 J. Giandhari, D. Doolabh, S. Pillay, E.J. San, K. Wibmer, B.T.  
228 Sewell, J. Lourenço, L. Carlos, J. Alcantara, S.L. Kosakovsky, S.  
229 Weaver, D. Martin, R.J. Lessells, J.N. Bhiman, C. Williamson, T. De  
230 Oliveira, Emergence and rapid spread of a new severe acute  
231 respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage  
232 with multiple spike mutations in South Africa, *Arghavan*  
233 *Alisoltani-Dehkordi.* 10 (2020) 2020.12.21.20248640.  
234 <https://doi.org/10.1101/2020.12.21.20248640>.
- 235 [8] C.K. Wibmer, F. Ayres, T. Hermanus, M. Madzivhandila, SARS-  
236 CoV-2 501Y . V2 escapes neutralization by South African COVID-  
237 19 donor plasma, *BioRxiv Prepr.* (2021).

238 <https://doi.org/https://doi.org/10.1101/2021.01.18.427166>doi:

239 [9] <https://corona-maps.live/gisaid/>

240 [10] W. Zeng, G. Liu, H. Ma, D. Zhao, Y. Yang, M. Liu, Biochemica  
241 characterisation of SARS-VoV-2 nucleocapsid protein, Biochem.  
242 Biophys. Research Commun. 527 (2020) 618–623.

243 <https://doi.org/https://doi.org/10.1016/j.bbrc.2020.04.136>.

244

245

246 **Highlights:**

- 247 • **PanBio SARS-CoV-2 RTD performs well in a field evaluation with high disease**  
248 **prevalence**
- 249 • **Good concordance between RT-PCR and RTD in patients with 501Y.v2 variant**  
250 **infection.**
- 251 • **RT-PCR on the antigen swab enables a more direct comparison of methods.**

252